Marion Merrell Dow withdraws Tenuate Dospan

18 June 1995

- Following last month's proposals by the UK Department of Health regarding the use of anti-obesity drugs, Marion Merrell Dow has said it is withdrawing its Tenuate Dospan (diethylpropion) product from sale once current stocks are exhausted. The only other brand of the drug, Wyeth's Apisate, was withdrawn from sale last month. A spokesman for MMD noted that prescribing levels for the drug were very low in any case, and that the new proposals would likely drive them down even lower.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight